Skip to main content
. 2022 Nov 17;22:467. doi: 10.1186/s12876-022-02528-y

Table 1.

Patient Demographics for group 1, 2, and 3

N reported Group 1 (N = 12) Group 2 (N = 37) Group 3 (N = 26) Combined P-value
Age 74 63.0 (58.2–68.2) 64.0 (58.0–68.0) 63.0 (59.0–69.0) 63.0 (58.2–69.0) 0.921
Gender 75 0.939
Female 3 (25%) 10 (27%) 6 (23%) 19 (25%)
Male 9 (75%) 27 (73%) 20 (77%) 56 (75%)
Race 75 0.735
American Indian /Alaska 0 (0%) 1 (3%) 0 (0%) 1 (1%)
Asian 0 (0%) 2 (5%) 1 (4%) 3 (4%)
Black 0 (0%) 4 (11%) 4 (15%) 8 (11%)
Native Hawaiian 0 (0%) 1 (3%) 0 (0%) 1 (1%)
Other 0 (0%) 1 (3%) 1 (4%) 2 (3%)
Unknown 2 (17%) 1 (3%) 1 (4%) 4 (5%)
White 10 (83%) 27 (73%) 19 (73%) 56 (75%)
Ethnicity 75 0.499
Hispanic or Latino 1 (8%) 1 (3%) 2 (8%) 4 (5%)
Non-Hispanic 9 (75%) 34 (92%) 22 (85%) 65 (87%)
Unknown 2 (17%) 2 (5%) 1 (4%) 5 (7%)
Other 0 (0%) 0 (0%) 1 (4%) 1 (1%)
Causes of Cirrhosis
Alcohol 75 0.094
Yes 2 (17%) 11 (30%) 2 (8%) 15 (20%)
No 10 (83%) 26 (70%) 24 (92%) 60 (80%)
Hepatitis B 75 0.508
Yes 0 (0%) 3 (8%) 1 (4%) 4 (5%)
No 12 (100%) 34 (92%) 25 (96%) 71 (95%)
Hepatitis C 75 0.869
Yes 5 (42%) 15 (41%) 9 (35%) 29 (39%)
No 7 (58%) 22 (59%) 17 (65%) 46 (61%)
NASH 75 0.011
Yes 4 (33%) 1 (3%) 3 (12%) 8 (11%)
No 8 (67%) 36 (97%) 23 (88%) 67 (89%)
Other 75 0.908
Yes 1 (8%) 2 (5%) 2 (8%) 5 (7%)
No 11 (92%) 36 (97%) 23 (88%) 67 (89%)
Bilirubin 74 0.800 (0.675–0.925) 1.05 (0.600–1.625) 0.700 (0.500–0.900) 0.800 (0.600–1.300) 0.023
Albumin 74 3.60 (3.18–3.92) 3.50 (3.20–3.68) 3.35 (3.08–3.60) 3.50 (3.10–3.70) 0.324
Ascites 75 0.014
Yes 2 (17%) 16 (43%) 3 (12%) 21 (28%)
No 10 (83%) 21 (57%) 23 (88%) 54 (72%)
Hepatic Encephalopathy 75 0.333
Yes 1 (8%) 1 (3%) 0 (0%) 2 (3%)
No 11 (92%) 36 (97%) 26 (100%) 73 (97%)
MELD 70 8.0 (7.0–9.5) 10.0 (8.0–12.0) 7.0 (6.0–9.0) 9.0 (7.0–11.0)  < 0.001
Child Pugh Class 70  < 0.001
Class A 12 (100%) 14 (39%) 18 (82%) 44 (63%)
Class B/C 0 (0%) 22 (61%) 4 (18%) 26 (37%)
HHS Vulnerability Disclosure